Nuclera Accelerates AI-Driven Antibody Engineering with $87 Million Capital Infusion
January 14, 2026, 3:38 am
Location: United Kingdom, England, Sheffield
Employees: 201-500
Founded date: 2014
Total raised: $8.95B
Nuclera secures an additional $12 million, elevating Series C funding to $87 million. This critical capital fuels accelerated antibody engineering on its eProtein Discovery benchtop system. The biotech leader targets AI-enabled protein development, focusing on generating vital, high-quality datasets for next-generation biologics. This strategic expansion promises to revolutionize drug discovery. It streamlines complex workflows. It reduces development costs. It speeds therapeutic breakthroughs. Nuclera aims to become a foundational platform for protein and antibody engineering. Its proven system tackles bottlenecks, expanding from membrane proteins to global market reach, accelerating future medicine development.
Biotech firm Nuclera drives innovation. It recently announced a significant funding extension. An additional $12 million now joins its Series C round. This boosts the total capital to $87 million. Elevage Medical Technologies led the investment. Jonathan Milner also played a key role. Existing investors, including British Business Bank and GK Goh, participated. This capital injection reinforces market confidence in Nuclera's vision.
The new funding has a clear purpose. It accelerates core development. Nuclera integrates antibody expression. It adds binding validation capabilities. These enhancements target the eProtein Discovery system. This benchtop platform is already powerful. It simplifies protein expression. It streamlines purification workflows. Now, it expands its reach into critical antibody applications.
Antibody engineering stands as a rapidly growing segment. It is vital for biologics R&D. Nuclera positions its eProtein Discovery system within this forefront. The company addresses a pressing industry need. Scientists require scalable, high-quality datasets. These datasets power advanced AI models. Such models are transforming drug discovery. Nuclera's platform aims to generate these essential datasets.
The eProtein Discovery system integrates unique technologies. Cell-free expression systems are central. Novel digital microfluidics enhance operations. Robust screening data provides critical insights. Together, these elements empower researchers. They perform multiplex protein screening. They characterize proteins efficiently. Small-scale expression is managed in-house. This comprehensive approach reduces development friction.
Traditional protein expression is slow. It is resource-intensive. It carries high uncertainty. Nuclera’s system changes this paradigm. It provides clear guidance early on. Researchers identify promising protein candidates faster. This significantly reduces time. It cuts costs. It boosts the probability of success in drug discovery efforts.
Expanding eProtein Discovery to antibodies is strategic. It moves Nuclera into AI-enabled protein engineering. The platform will perform end-to-end workflows. This includes expression, purification, and binding validation. Full-format antibodies are managed within one integrated system. It operates at high-throughput. This generates standardized data. High-quality data is essential for AI model training.
Nuclera's journey reflects continuous advancement. Since its prior Series C funding in 2024, the company achieved key milestones. It added a membrane protein workflow. Membrane proteins are notoriously challenging. The eProtein Discovery system successfully tackles them. This demonstrates platform versatility and robustness.
Global expansion also progressed significantly. Nuclera broadened customer access. New distribution partnerships cover APAC. They extend into the Middle East. This strategic reach makes the eProtein Discovery platform more accessible. More researchers can leverage its benefits worldwide.
Collaborations further strengthened Nuclera's ecosystem. A partnership with Cytiva was initiated. This aims to accelerate protein characterization. It speeds the path from DNA to purified proteins. Better understanding of drug-target interactions emerges. This collaboration enhances upstream drug development processes.
Commercial validation also arrived. The eProtein Discovery system found its first CRO implementation. Domainex, a Contract Research Organization, installed the platform. This streamlines their protein production services. It validates the system's commercial and scientific impact. It shows the platform's utility in diverse research and industry settings.
The company's mission remains clear. It accelerates discovery. It provides rapid access to functional proteins. These proteins are essential for drug discovery research. The eProtein Discovery system supports this core mission. It allows for quick generation of soluble, purified proteins. This happens in under 48 hours. Traditional cell-based methods often take months. Nuclera dramatically shortens these critical timelines.
Dr. Jonathan Milner, Chairman of Nuclera's Board, highlighted industry bottlenecks. He noted slow, fragmented antibody synthesis processes. Nuclera's team excels in microfluidics. Their success with challenging membrane proteins is evident. This unique combination positions them to transform antibody development. They address critical pain points in biologics.
The future of biologics discovery is intertwined with AI. AI models demand robust, structured data. Nuclera provides the tools to create this data. Its platform facilitates rapid experimentation. It generates consistent, high-quality results. This feeds the AI engines. It powers next-generation therapeutic advancements across the globe.
Nuclera is not just developing a tool. It is building a foundation. It creates an infrastructure for future protein engineering. It aims to accelerate therapeutic timelines globally. This impacts countless patients. It brings new treatments to market faster. The $87 million funding empowers this ambitious vision. The company remains a critical player in biotech innovation. Its impact on drug discovery continues to grow.
Biotech firm Nuclera drives innovation. It recently announced a significant funding extension. An additional $12 million now joins its Series C round. This boosts the total capital to $87 million. Elevage Medical Technologies led the investment. Jonathan Milner also played a key role. Existing investors, including British Business Bank and GK Goh, participated. This capital injection reinforces market confidence in Nuclera's vision.
The new funding has a clear purpose. It accelerates core development. Nuclera integrates antibody expression. It adds binding validation capabilities. These enhancements target the eProtein Discovery system. This benchtop platform is already powerful. It simplifies protein expression. It streamlines purification workflows. Now, it expands its reach into critical antibody applications.
Antibody engineering stands as a rapidly growing segment. It is vital for biologics R&D. Nuclera positions its eProtein Discovery system within this forefront. The company addresses a pressing industry need. Scientists require scalable, high-quality datasets. These datasets power advanced AI models. Such models are transforming drug discovery. Nuclera's platform aims to generate these essential datasets.
The eProtein Discovery system integrates unique technologies. Cell-free expression systems are central. Novel digital microfluidics enhance operations. Robust screening data provides critical insights. Together, these elements empower researchers. They perform multiplex protein screening. They characterize proteins efficiently. Small-scale expression is managed in-house. This comprehensive approach reduces development friction.
Traditional protein expression is slow. It is resource-intensive. It carries high uncertainty. Nuclera’s system changes this paradigm. It provides clear guidance early on. Researchers identify promising protein candidates faster. This significantly reduces time. It cuts costs. It boosts the probability of success in drug discovery efforts.
Expanding eProtein Discovery to antibodies is strategic. It moves Nuclera into AI-enabled protein engineering. The platform will perform end-to-end workflows. This includes expression, purification, and binding validation. Full-format antibodies are managed within one integrated system. It operates at high-throughput. This generates standardized data. High-quality data is essential for AI model training.
Nuclera's journey reflects continuous advancement. Since its prior Series C funding in 2024, the company achieved key milestones. It added a membrane protein workflow. Membrane proteins are notoriously challenging. The eProtein Discovery system successfully tackles them. This demonstrates platform versatility and robustness.
Global expansion also progressed significantly. Nuclera broadened customer access. New distribution partnerships cover APAC. They extend into the Middle East. This strategic reach makes the eProtein Discovery platform more accessible. More researchers can leverage its benefits worldwide.
Collaborations further strengthened Nuclera's ecosystem. A partnership with Cytiva was initiated. This aims to accelerate protein characterization. It speeds the path from DNA to purified proteins. Better understanding of drug-target interactions emerges. This collaboration enhances upstream drug development processes.
Commercial validation also arrived. The eProtein Discovery system found its first CRO implementation. Domainex, a Contract Research Organization, installed the platform. This streamlines their protein production services. It validates the system's commercial and scientific impact. It shows the platform's utility in diverse research and industry settings.
The company's mission remains clear. It accelerates discovery. It provides rapid access to functional proteins. These proteins are essential for drug discovery research. The eProtein Discovery system supports this core mission. It allows for quick generation of soluble, purified proteins. This happens in under 48 hours. Traditional cell-based methods often take months. Nuclera dramatically shortens these critical timelines.
Dr. Jonathan Milner, Chairman of Nuclera's Board, highlighted industry bottlenecks. He noted slow, fragmented antibody synthesis processes. Nuclera's team excels in microfluidics. Their success with challenging membrane proteins is evident. This unique combination positions them to transform antibody development. They address critical pain points in biologics.
The future of biologics discovery is intertwined with AI. AI models demand robust, structured data. Nuclera provides the tools to create this data. Its platform facilitates rapid experimentation. It generates consistent, high-quality results. This feeds the AI engines. It powers next-generation therapeutic advancements across the globe.
Nuclera is not just developing a tool. It is building a foundation. It creates an infrastructure for future protein engineering. It aims to accelerate therapeutic timelines globally. This impacts countless patients. It brings new treatments to market faster. The $87 million funding empowers this ambitious vision. The company remains a critical player in biotech innovation. Its impact on drug discovery continues to grow.